Serum miRNA-21: Elevated Levels in Patients With Metastatic Hormone-Refractory Prostate Cancer and Potential Predictive Factor for the Efficacy of Docetaxel-Based Chemotherapy
Serum miRNA-21: Elevated Levels in Patients With Metastatic Hormone-Refractory Prostate Cancer and Potential Predictive Factor for the Efficacy of Docetaxel-Based Chemotherapy
复制标题
血清 miRNA-21：转移性激素难治性前列腺癌患者的水平升高以及多西紫杉醇化疗疗效的潜在预测因素
DOI：
10.1002/pros.21246
复制
发表时间：
2011-02-15
期刊：
影响因子：
2.8
通讯作者：
Ye, Ding-Wei
中科院分区：
文献类型：
--
作者：
Zhang, Hai-Liang;Yang, Li-Feng;Ye, Ding-Wei
背景miR-21被认为是一种具有负调节肿瘤抑制基因表达活性的“癌微RNA”。然而，其在前列腺癌（CaP）中的作用尚未得到充分证实。本研究旨在评估血清miR-21在CaP进展中的潜在功能。收集56名患者的血清样品用于测量miR-21，所述患者包括20名患有局限性CaP的患者、20名患有雄激素依赖性前列腺癌（ADPC）的患者、10名患有难治性前列腺癌（HRPC）的患者和6名患有良性前列腺增生（BPH）的患者。10例HRPC患者接受以紫杉醇为基础的化疗。通过特异性TaqMan qRT-PCR方法测定miR-21的定量。ADPC和HRPC患者血清miR-21水平与血清PSA水平相关，P值分别为0.012和0.049。BPH、局限性CaP和PSA水平4 ng/ml的ADPC之间血清miR-21水平无显著差异。10例HRPC患者中有6例在化疗后达到部分缓解，PSA水平下降>50%。与化疗敏感患者相比，紫杉醇化疗耐药患者血清miR-21水平较高，P= 0.032。血清miR-21水平在HRPC患者中升高，特别是在对紫杉醇化疗耐药的患者中。它可能适用于作为一个标志物，指示转化为激素难治性疾病，并为基础的紫杉醇化疗的疗效的一个潜在的预测。前列腺71：326-331，2011年。(C)2010 Wiley-Liss，Inc.
BACKGROUND. miR-21 has been recognized as an "onco-microRNA" with the activity of negatively modulating the expression of tumor-suppressor genes. However, its role in prostate cancer (CaP) has not been well-documented. We designed this study to assess the potential function of serum miR-21 in the progression of CaP.METHODS. Serum samples of 56 patients, including 20 patients with localized CaP, 20 with androgen-dependent prostate cancer (ADPC), 10 with hormone-refractory prostate cancer (HRPC), and 6 with benign prostatic hyperplasia (BPH), were collected for the measurement of miR-21. The 10 HRPC patients were administered docetaxel-based chemotherapy. Quantification of miR-21 was assayed by specific TaqMan qRT-PCR.RESULTS. Serum miR-21 level was found to correlate to serum PSA level in patients with ADPC and HRPC, P = 0.012 and 0.049, respectively. There was no significant difference in serum miR-21 level between BPH, localized CaP and ADPC with PSA level 4 ng/ml. Six of the 10 HRPC patients reached partial remission with a decreased PSA level of >50% after chemotherapy. Serum miR-21 levels were higher in patients who were resistant to docetaxel-based chemotherapy when compared to those sensitive to chemotherapy, P=0.032.CONCLUSIONS. Serum miR-21 levels are elevated in HRPC patients, especially in those resistant to docetaxel-based chemotherapy. It may be applicable as a marker to indicate the transformation to hormone refractory disease, and a potential predictor for the efficacy of docetaxel-based chemotherapy. Prostate 71: 326-331, 2011. (C) 2010 Wiley-Liss, Inc.